Investigational drug · Phase 3
cendakimab
Also called: CC-93538, BMS-986355
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Eosinophilic Esophagitis.
Phase 3Last checked: Nov 19, 2026Latest source record: Apr 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
9
Any phase or sponsor naming "cendakimab"
First trial start
2022
Aug 9, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "cendakimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Eosinophilic Esophagitis
Approved drugs for the same conditions: Eosinophilic esophagitis · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "cendakimab" as an intervention, largest first.
- A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic EsophagitisPivotal-lookingCompleted
CelgeneBristol Myers Squibb (BMY)
NCT04753697 · 430 participants · Start Feb 22, 2021 · Primary completion Jan 11, 2024
Drug: CC-93538 · For: Eosinophilic Esophagitis
Sites: Birmingham, Alabama; Tuscaloosa, Alabama; Phoenix, Arizona · 212 sites in all
- Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic EsophagitisPivotal-lookingCompleted
CelgeneBristol Myers Squibb (BMY)
NCT04991935 · 367 participants · Start Aug 9, 2022 · Primary completion Aug 14, 2025
Drug: CC-93538 · For: Eosinophilic Esophagitis
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 167 sites in all
- A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic DermatitisPivotal-lookingCompleted
CelgeneBristol Myers Squibb (BMY)
NCT04800315 · 221 participants · Start May 14, 2021 · Primary completion Jul 20, 2022
Drug: CC-93538 · For: Dermatitis, Atopic; Eczema
Sites: Birmingham, Alabama; Hot Springs, Arkansas; Fountain Valley, California · 157 sites in all
- A Study to Evaluate the Drug Levels of Cendakimab Delivered Subcutaneously in Healthy ParticipantsPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT05337345 · 104 participants · Start May 2, 2022 · Primary completion Dec 15, 2022
Drug: Cendakimab · For: Healthy Volunteers
Sites: Anaheim, California
- Dose Ranging Study of RPC4046 in Eosinophilic EsophagitisPivotal-lookingCompleted
CelgeneBristol Myers Squibb (BMY)
NCT02098473 · 100 participants · Start Aug 31, 2014 · Primary completion Feb 17, 2016
Drug: RPC4046; Placebo · For: Eosinophilic Esophagitis
Sites: Scottsdale, Arizona; Tucson, Arizona; Oceanside, California · 30 sites in all
- A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Participants With Eosinophilic GastroenteritisPivotal-lookingCompleted
CelgeneBristol Myers Squibb (BMY)
NCT05214768 · 48 participants · Start Mar 4, 2022 · Primary completion Jul 2, 2024
Drug: CC-93538; Placebo · For: Eosinophilic Gastroenteritis
Sites: Gifu, Japan; Himeji-shi, Japan; Nishinomiya, Japan · 25 sites in all
AbbVieAbbVie (ABBV)
NCT00986037 · 47 participants (planned) · Start Oct 2009 · Primary completion Jul 2010
Drug: ABT-308; ABT-308 and 2 more · For: Asthma
- A Study to Evaluate the Safety and Tolerability of Cendakimab in Chinese Healthy ParticipantsCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT05638282 · 25 participants · Start Feb 15, 2023 · Primary completion Jun 27, 2023
Drug: Cendakimab; Placebo · For: Healthy Participants
Sites: Guangzhou, China
CelgeneBristol Myers Squibb (BMY)
NCT05175352 · 16 participants · Start Jun 7, 2022 · Primary completion Oct 11, 2024
Drug: Cendakimab; CYP substrates · For: Eosinophilic Esophagitis
Sites: Tucson, Arizona; Los Angeles, California; San Diego, California · 12 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Evaluation of the Effect of Cendakimab on the Pharmacokinetics of CYP Probe Drugs in Patients With Eosinophilic Esophagitis.
Zhang P, Charriez CM, Murthy B, et al. · Clin Transl Sci 2026
- Efficacy of Biological and Steroid Therapies in Adolescent and Adult Patients With Eosinophilic Esophagitis: A Systematic Review and Network Meta-Analysis With Meta-Regression.
Al Hayek M, Lucendo AJ, Savarino EV, et al. · Clin Gastroenterol Hepatol 2026
- Cendakimab for Eosinophilic Gastritis and Duodenitis in Japanese Adults and Adolescents: Results from a Phase 3 Randomized Controlled Trial.
Kinoshita Y, Oka S, Matsushima K, et al. · Am J Gastroenterol 2026
- Latent Variable Indirect Response Modeling of Cendakimab Exposure-Response for Longitudinal Dysphagia Days Using a Combined Uniform-Binomial Likelihood Framework.
Du S, Wojciechowski J, Zhang P, et al. · CPT Pharmacometrics Syst Pharmacol 2026
- Pruritic rash secondary to cendakimab, an investigative IL-13 inhibitor.
Gamada DM, Crimmins J, Leiman DA, et al. · JAAD Case Rep 2026
- Inflammatory and fibrotic biomarkers in patients with atopic dermatitis treated with cendakimab.
Li J, Gilvary C, Gao L, et al. · J Allergy Clin Immunol Glob 2026
Also in development for Eosinophilic Esophagitis
- barzolvolimabCDX-0159Phase 37 trials
Celldex Therapeutics · Chronic Spontaneous Urticaria, Chronic Inducible Urticaria, Cold Urticaria
- EP-104GIPhase 21 trial
Eupraxia Pharmaceuticals Inc. · Eosinophilic Esophagitis
- NDX-3315Phase 21 trial
NexEos Diagnostics, Inc. · Eosinophilic Esophagitis
- NDX-3324Phase 21 trial
NexEos Diagnostics, Inc. · Eosinophilic Esophagitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Bristol Myers Squibb.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.